Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK)

Historical Holders from Q2 2019 to Q3 2025

Symbol
STOK on Nasdaq
CUSIP
86150R107
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
54.7M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
67.7M
Holdings value
$1.57B
% of all portfolios
0.015%
Grand Portfolio weight change
+0%
Number of holders
148
Number of buys
80
Number of sells
-62
Average Value change %
-0.01%
Average buys %
+0.001%
Average sells %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12.5% -7.86% $161M -$12.9M 6.87M -7.39% FMR LLC Sep 30, 2025
RTW INVESTMENTS, LP 9.99% $37.3M 5.31M RTW Investments, LP Dec 31, 2024
Redmile Group, LLC 8% $86.5M 4.38M Redmile Group, LLC Jun 30, 2025
BlackRock, Inc. 6.8% +16.7% $87.8M $14.4M 3.73M +19.7% BlackRock, Inc. Sep 30, 2025
MORGAN STANLEY 6.5% $24.1M 3.43M Morgan Stanley Dec 31, 2024
TORONTO DOMINION BANK 5.8% $74.6M 3.17M The Toronto-Dominion Bank Sep 30, 2025
BlackRock Portfolio Management LLC 4.7% -8% $22.8M -$1.72M 2.55M -7.04% BlackRock Portfolio Management LLC Jun 30, 2025
Skorpios Trust 4.1% -31.7% $44.6M -$19.8M 2.26M -30.7% Montrago Trustees Ltd Aug 22, 2025

Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 67.7M $1.57B +$64.5M $23.50 148
2025 Q2 65.5M $744M +$30.2M $11.35 133
2025 Q1 63.4M $422M +$30.3M $6.65 124
2024 Q4 58.1M $640M -$5.64M $11.03 129
2024 Q3 58.2M $715M -$45.8M $12.29 117
2024 Q2 61.3M $828M +$97.1M $13.51 115
2024 Q1 54.1M $730M +$114M $13.50 103
2023 Q4 11.2K $58.8K $5.26 1
2023 Q3 43.9M $173M -$18.2M $3.94 96
2023 Q2 46.5M $494M +$20.7M $10.63 96
2023 Q1 44.6M $372M +$14.2M $8.33 96
2022 Q4 40.3M $372M -$19.2M $9.23 105
2022 Q3 38.9M $499M +$1.44M $12.84 95
2022 Q2 40.4M $535M +$3.68M $13.21 84
2022 Q1 38.8M $817M +$73M $21.05 95
2021 Q4 35.4M $848M +$26.4M $23.99 90
2021 Q3 19.3M $492M -$27.8M $25.44 88
2021 Q2 20.2M $680M -$703M $33.66 96
2021 Q1 38.4M $1.49B -$15.7M $38.84 104
2020 Q4 38.4M $2.38B +$253M $61.93 90
2020 Q3 34.6M $1.16B +$2.94M $33.49 89
2020 Q2 34.9M $825M +$9.8M $23.83 69
2020 Q1 34.6M $791M +$23.3M $22.90 65
2019 Q4 33.5M $948M +$22.4M $28.32 63
2019 Q3 15.9M $339M +$30.1M $21.49 52
2019 Q2 14.2M $408M +$408M $29.17 46